Holtzman Adam L, Seidensaal Katharina, Iannalfi Alberto, Kim Kyung Hwan, Koto Masashi, Yang Wan-Chin, Shiau Cheng-Ying, Mahajan Anita, Ahmed Safia K, Trifiletti Daniel M, Peterson Jennifer L, Koffler Daniel M, Vallow Laura A, Hoppe Bradford S, Rutenberg Michael S
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.
Department of Radiation Oncology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Cancers (Basel). 2023 Oct 17;15(20):5021. doi: 10.3390/cancers15205021.
Skull-base chordoma and chondrosarcoma are rare radioresistant tumors treated with surgical resection and/or radiotherapy. Because of the established dosimetric and biological benefits of heavy particle therapy, we performed a systematic and evidence-based review of the clinical outcomes of patients with skull-base chordoma and chondrosarcoma treated with carbon ion radiotherapy (CIRT). A literature review was performed using a MEDLINE search of all articles to date. We identified 227 studies as appropriate for review, and 24 were ultimately included. The published data illustrate that CIRT provides benchmark disease control outcomes for skull-base chordoma and chondrosarcoma, respectively, with acceptable toxicity. CIRT is an advanced treatment technique that may provide not only dosimetric benefits over conventional photon therapy but also biologic intensification to overcome mechanisms of radioresistance. Ongoing research is needed to define the magnitude of benefit, patient selection, and cost-effectiveness of CIRT compared to other forms of radiotherapy.
颅底脊索瘤和软骨肉瘤是罕见的抗辐射肿瘤，通常采用手术切除和/或放射治疗。鉴于重粒子治疗已明确的剂量学和生物学优势，我们对接受碳离子放疗（CIRT）的颅底脊索瘤和软骨肉瘤患者的临床结果进行了系统且基于证据的综述。通过对MEDLINE中所有文章进行检索来开展文献综述。我们确定了227项适合综述的研究，最终纳入了24项。已发表的数据表明，CIRT分别为颅底脊索瘤和软骨肉瘤提供了具有可接受毒性的基准疾病控制结果。CIRT是一种先进的治疗技术，不仅可能比传统光子治疗具有剂量学优势，还能增强生物学效应以克服抗辐射机制。与其他放疗形式相比，仍需开展进一步研究来明确CIRT的获益程度、患者选择和成本效益。
